Cryoport Systems

Just Released: Cryoport $CYRX announced Q2 2024 Financial Results. Check out our earnings recap below and full report here: https://lnkd.in/gddF-6wH ▪️ Commercial Cell & Gene Therapy revenue increased 𝟱𝟭% year-over-year and 𝟮𝟬% sequentially ▪️ A record total of 𝟲𝟴𝟰 global clinical trials supported as of June 30, 2024 ▪️ Cost reduction initiatives anticipated to result in approximately $𝟮𝟮 𝗺𝗶𝗹𝗹𝗶𝗼𝗻 of annualized cost savings and drive Cryoport towards its goal of profitable growth, as well as a return to positive Adjusted EBITDA in 2025

Congratulations to client Abeona Therapeutics on the resubmission of their Biologics License Application (BLA) for prademagene zamikeracel (pz-cel) to the U.S. FDA. This investigational autologous cell-based gene therapy represents a significant potential advancement for patients with recessive dystrophic epidermolysis bullosa (RDEB). We are proud to support innovative companies and therapies that aim to improve the lives of patients facing rare diseases. https://lnkd.in/eQZtYE8U $CYRX #bla #cgt #cellandgenetherapy #genetherapy #autologous

We extend our heartfelt congratulations to our client, Sarepta Therapeutics, on the recognition of their new therapy for Duchenne muscular dystrophy as one of TIME's Best Inventions of 2024! This accolade highlights the remarkable innovation and dedication that Sarepta brings to the rare disease community. At Cryoport Systems, we are proud to support organizations like Sarepta in their mission to develop life-changing therapies. https://lnkd.in/gaS6fdid $CYRX #lifesciences #advancedtherapies #cgt

We are excited to share that Cryoport Inc. has been recognized as a finalist in two categories at the Life Science Sales and Marketing (LSSM) Awards: Marketing Team of the Year and Campaign of the Year for the Enabling the Future of Medicine™ rebrand.   This achievement highlights the collective efforts of our dedicated marketing team and the entire Cryoport organization in advancing our mission to support clients in developing life-saving therapies. Congratulations to everyone involved in this effort. We are honored to be part of such a distinguished group, and we look forward to the announcement of the winners in November!

Cryoport Systems' longstanding dedication to quality has a sole focus on supporting #LifeSciences. Our platform of solutions was purpose-built to #EnableTheOutcome for organizations worldwide through our BioServices and biostorage, shipping systems, logistics, cryopreservation, & consulting services. $CYRX Learn more: https://cyrx.co/4caF2rg

Trust Cryoport Systems' biobanking services to safeguard your valuable biomaterials. Our validated IT solutions and data management ensure the integrity and traceability of samples throughout their entire life cycle, meeting the most stringent industry standards. Learn More: https://cyrx.co/4bL14jr #Traceability #Integrity $CYRX

The cell and gene therapy supply chain is complex, but overcoming bottlenecks is key to timely patient delivery. Join industry experts from Cryoport Systems and Advent Bioservices for an in-depth webinar on strategies to enhance efficiency at every stage – from sourcing starting materials to post-manufacturing logistics.   Don’t miss out on insights that could transform your approach to supply chain management. Watch the on-demand recording: https://lnkd.in/gtyG6yM5

Cryoport Systems extends its congratulations to our customer, Lyell Immunopharma, on their acquisition of ImmPACT Bio.   We’re proud to support Lyell with advanced supply chain and logistics solutions as they move closer to their goal of delivering more durable, effective cell and gene therapies to patients. $CYRX #CGT #CellTherapy #CAR-T #AdvancedTherapies #ColdChain #SupplyChain

From pre-clinical studies to commercialization, Cryoport Systems is your supply chain partner enabling cell therapy success. Trust us to manage, store and deliver your therapies safely and efficiently to patients worldwide. #CellTherapySuccess #GlobalDistribution $CYRX Learn More: https://cyrx.co/3yYwuVA

Are you navigating the complexities of autologous cell therapy supply chains? On November 14th, Amy Hines, Vice President of Apheresis Strategy at Cryoport Systems, joins a panel of industry leaders from NMDP BioTherapies and Orchard Therapeutics - U.S. to discuss when outsourcing collection center qualification makes sense. Learn from experienced professionals as they share real-world insights on improving the efficiency, quality, and scalability of your operations. Register now to secure your place: https://lnkd.in/gQ4qpQ8k $CYRX #Cryopreservation #CellTherapy #Autologous #SupplyChain